Pharscin Pharma(002907)2023-06-27 09:31Business Performance and Growth - The company's five exclusive traditional Chinese medicine (TCM) products, including Ganju Bingmei Tablets and Tongxie Ning Granules, grew by 17% in 2022 [2] - The company has established a "3-3-3" pipeline strategy, aiming to initiate, submit, and launch at least three new products annually [2] - The company expects to launch at least three new drug varieties annually over the next five years, providing stable profit increments [6] Product Development and Innovation - The company has four self-developed Class 1.1 innovative oncology drugs in the pipeline, covering various solid tumors [4] - Two oncology projects are nearing the PCC stage, with IND-enabling studies expected by the end of 2023 [5] - The company has successfully challenged its first generic drug patent and achieved expected results in a high-variability generic drug pre-BE trial [5] Market Expansion and Strategy - The company has launched its own brand "Quchang" for Orlistat Capsules, which is in the market introduction phase [2] - The company has entered the special medical food (FSMP) market, with three FSMP projects in the pilot stage [3] - The company has built the first FSMP production line in the Sichuan-Chongqing region and expects to obtain the first FSMP production license within three years [3] Health and Wellness Products - The company has introduced the "Yanpin Senhuo" series of health products, including Hawthorn Chicken Gizzard Soft Candy and Yuan Ye Tea, which have shown positive market response [4] - The company is leveraging its pharmaceutical expertise to expand into the health and wellness consumer market, aiming to find new growth points [4] Regulatory and Quality Assurance - The company underwent FDA cGMP international certification inspection in the first half of 2023 and is awaiting results [4] - Passing cGMP certification will enable the company to internationalize its production quality and open up capacity for CMO and CDMO businesses [4] Financial Outlook - The company is confident in achieving revenue and net profit growth in 2023, with hospital terminal diagnostics returning to normal levels [6] - The company plans to deepen its presence in the health and wellness consumer market through new media platforms like TikTok and Xiaohongshu to drive sales growth [6]